A fast liquid chromatographic assay with mass spectrometric detection (LC/MS) has been developed and validated for the simultaneous determination of methadone (MT), its primary metabolite, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) and alprazolam, in human plasma. The extraction procedure was performed with automatic solid phase extraction, and the compounds were separated with a Sunfire column using a gradient mode. Deuterated analogues for all of the analytes of interest were used for quantitation. Limits of detection (LOD) were established between 0.5 and 1 ng/ml. Linearity was obtained over a range of 2-2,000 ng/ml with an average correlation coefficient (R(2)) of >0.99. Intra- and inter-batch coefficients of variation and relative mean errors were less than 10% for all analytes and concentrations. The recoveries were higher than 50.0% in all cases. The method proved to be suitable for evaluation of plasma obtained from patients enrolled in a MT-maintenance program who are frequently treated with alprazolam as a sedative.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jchromb.2006.02.013DOI Listing

Publication Analysis

Top Keywords

determination methadone
8
alprazolam human
8
human plasma
8
methadone 2-ethylidene-15-dimethyl-33-diphenylpyrrolidine
4
2-ethylidene-15-dimethyl-33-diphenylpyrrolidine alprazolam
4
plasma liquid
4
liquid chromatography-electrospray
4
chromatography-electrospray ionization
4
ionization mass
4
mass spectrometry
4

Similar Publications

Receipt of medications for opioid use disorder among rural and urban veterans health administration patients.

Drug Alcohol Depend Rep

March 2025

Center to Improve Veteran Involvement in Care, VA Portland Health Care System,  3710 SW US Veterans Hospital Rd, Portland, OR 97239, United States.

Aim: We examined differences in medications for opioid use disorder (MOUD) receipt between rural and urban veteran patients following initiatives within the US Department of Veterans Affairs (VA) to expand access to MOUD.

Methods: Data for this retrospective cohort study were obtained from the VA Corporate Data Warehouse, which contains national electronic health record data for all VA patients. The analytic sample included all patients diagnosed with OUD from 10/1/2018-9/30/20.

View Article and Find Full Text PDF

Introduction: The QTc prolongation effect of methadone has been extensively studied at higher doses commonly used in opioid dependence maintenance therapy, but evidence remains limited regarding its impact at the lower doses typically prescribed for cancer pain. This study aims to evaluate the effect of oral methadone on QTc intervals in cancer pain patients.

Methods: A retrospective analysis was performed on adult patients initiated on oral methadone therapy for cancer.

View Article and Find Full Text PDF

Rationale And Objectives: In vivo receptor interactions vary as a function of behavioral endpoint, with key differences between reflexive and non-reflexive measures that assess the motivational aspects of pain and pain relief. There have been no assessments of D dopamine agonist / mu opioid receptor (MOR) agonist interactions in non-reflexive behavioral measures of pain. We examined the hypothesis that D/MOR mixtures show enhanced effectiveness in blocking pain depressed behaviors while showing decreased side effects such as sedation and drug reward.

View Article and Find Full Text PDF

Hepatitis C (HCV) disproportionately affects people who inject drugs (PWID). Despite availability of safe and effective treatment, HCV treatment access and uptake among PWID in low- and middle-income countries (LMICs) has been limited. Understanding the lived experiences of PWID in these settings who have undergone treatment provides the opportunity to gain insight into how to implement treatment programs that meet the needs of this population.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!